An MCAS flare is common patient language for sudden symptom worsening, but it is not a separate formal diagnosis. Under strict MCAS criteria, the clinically important episodes are recurrent, abrupt and systemic, and they involve at least two organ systems. They can resemble anaphylaxis.
Typical systemic episodes may settle within several hours, while the broader patient-used word “flare” has no validated universal duration.
What is an MCAS flare?
An MCAS flare is patient-facing terminology for a period when symptoms get suddenly worse. It is not a separate diagnosis with its own criteria.
The more precise clinical concept is a systemic mast-cell activation episode. In strict consensus frameworks, mast cell activation syndrome is defined by recurrent episodes of that kind, plus objective biochemical evidence and a meaningful response to mediator-targeted treatment. Using the word “flare” does not by itself confirm MCAS.
MCAS is also not simply too much histamine. Mast cells release many mediators, and histamine is only one. Our comparison of MCAS vs histamine intolerance covers the difference, and the page on histamine overload explains why that popular phrase is not a diagnosis.
What does an MCAS flare feel like?
A systemic episode tends to start abruptly and involve more than one part of the body. It can feel like an allergic reaction, sometimes with no clear allergen. The main symptom domains are:
- Skin: itching, flushing, hives, swelling of deeper tissue (angioedema)
- Gastrointestinal: cramping, sudden diarrhea, vomiting
- Cardiovascular: low blood pressure, dizziness, confusion, near-fainting or fainting
- Respiratory: shortness of breath, wheeze, airway symptoms
- Eyes and nose: severe congestion, watery runny nose, sneezing, red eyes
A fast heart rate may accompany an episode, but it is nonspecific. Symptoms alone do not establish MCAS, because many other conditions can produce the same ones.
Which symptoms fit a systemic mast-cell activation episode?
The pattern matters more than any single symptom. A qualifying episode is abrupt, recurrent and clinically meaningful. It involves at least two organ systems, and it often looks like anaphylaxis.
Several common complaints do not define such an episode on their own:
- chronic fatigue
- headache
- brain fog
- chronic bloating
- isolated flushing
- chronic urticaria
- symptoms limited to one organ system
- waxing and waning symptoms without discrete episodes
They may coexist with MCAS or with another condition. They are not enough, by themselves, to identify a strict systemic episode. A 2025 practical review by Lee and Picard cautions specifically against relying on chronic nonspecific symptoms.
What can trigger an MCAS flare?
Triggers vary from person to person, and none applies to everyone. Possible trigger contexts that have been reported include:
- exercise
- high ambient temperature
- stressful events
- foods, in selected patients
- medications, including reactions related to NSAID hypersensitivity
- infections
- venoms
- surgery or procedures, where physiologic stress and medication exposures may contribute
Evidence for each of these is limited and uneven, and none is a universal trigger. Some exposures may cause secondary mast-cell activation rather than idiopathic MCAS, which means a trigger does not establish the diagnosis.
Food deserves a specific caution. Meal-linked episodes should not be assumed to be MCAS, and the practical review above advises evaluating for IgE-mediated food allergy when episodes occur mostly or only after meals.
How long does an MCAS flare last?
Strict systemic mast-cell activation episodes are described in consensus-based clinical literature as abrupt episodes that generally resolve within several hours. People use “MCAS flare” more broadly for longer periods of symptom worsening, but there is no validated universal duration for that broader use. We do not give a fixed number of days, because none has been established.
Fatigue can outlast the acute event. One practical review describes moderate-to-severe fatigue lasting up to about 24 hours after anaphylaxis. Lingering tiredness does not by itself mean mediator release is still going on.
So the honest answer has two layers. A discrete systemic episode usually settles in hours, and a drawn-out period of feeling worse is a different thing that needs its own explanation.
Why can symptoms last longer than the acute episode?
Several explanations are possible when symptoms continue past the acute phase:
- recovery and fatigue after a severe event
- continued or repeated exposure
- overlapping chronic symptoms
- another diagnosis
- broad patient use of the word “flare”
A stretch of weeks or months should not be treated as one continuous systemic mast-cell activation episode. If worsening keeps going, that is a reason to reassess, not to assume a single prolonged flare.
What should you do during a suspected MCAS flare?
Safety comes first, and the steps below are a general sequence, not a new plan. Follow the rescue plan your clinician gave you.
- Assess severity first.
- Follow your clinician-provided rescue or emergency plan.
- If anaphylaxis-level symptoms are present, use prescribed epinephrine according to that plan and seek emergency care.
- For milder symptoms, use clinician-approved non-emergency medicines as directed.
- Note symptom timing, which body systems were involved and any possible context or trigger.
- Frequent or atypical episodes need reassessment and longer-term planning.
Do not delay emergency treatment to obtain a diagnostic lab sample. This article does not give doses or a rescue plan, and no universal home rescue stack exists.
Which medicines may be part of an MCAS plan?
Medicines are individualized and clinician-directed. This section only clarifies roles, and it is not a treatment ladder.
- Epinephrine is the first-line acute treatment for anaphylaxis.
- Second-generation H1 antihistamines are commonly used for urticaria, angioedema, itching and other histamine-mediated symptoms. They are not diagnostic proof and not a substitute for epinephrine.
- H2-receptor blockers may be used as adjunctive therapy, especially for gastrointestinal symptoms. MCAS-specific benefit is not firmly established.
- Leukotriene modifiers may be used by clinician direction as adjunctive or preventive therapy. MCAS-specific efficacy trials are limited, and they are not an established acute rescue treatment.
- Cromolyn is a longer-term symptom-control option, especially for persistent gastrointestinal symptoms in selected patients. Evidence is limited, its effect is judged over longer periods, and it is not an acute rescue drug.
- Ketotifen has antihistamine and mast-cell-stabilizing properties. Evidence is limited, it is used in ongoing clinician-directed management, and it is not an acute rescue drug.
Omalizumab and systemic corticosteroids are specialist-directed topics. Corticosteroids are not first-line treatment for anaphylaxis.
When an MCAS flare may actually be anaphylaxis
A severe systemic mast-cell activation episode can meet anaphylaxis criteria. In that situation the emergency is anaphylaxis, not something to manage casually as a flare.
Call emergency services for:
- breathing difficulty
- throat or tongue swelling
- severe low blood pressure
- fainting
- a rapidly progressing reaction affecting several body systems
Antihistamines do not replace epinephrine for anaphylaxis. The 2023 anaphylaxis practice parameter by Golden and colleagues names epinephrine as first-line treatment. Do not wait it out.
| Pattern | Typical features | Duration / timing | What it means |
|---|---|---|---|
| Patient-described MCAS flare | Broad, nonstandardized patient term; may refer to a period of symptom worsening | Duration not standardized | Does not by itself confirm systemic mast-cell activation |
| Systemic mast-cell activation episode | Abrupt, recurrent, multisystem; often anaphylaxis-like | Generally resolves within several hours | Part of the clinical pattern considered under strict MCAS criteria |
| Anaphylaxis | Rapidly progressive systemic allergic or mast-cell mediator reaction; may involve airway, breathing or circulation | Rapid onset; an emergency | Epinephrine is first-line treatment |
| Chronic or single-system symptoms | Fatigue, brain fog, chronic urticaria, isolated flushing, chronic gastrointestinal symptoms | Persistent or waxing and waning, not discrete systemic episodes | Do not by themselves establish systemic MCAS |
When frequent “flares” need reassessment
Self-labeled flares are worth revisiting with a clinician when the picture does not fit a systemic episode pattern. Reassessment makes sense when:
- symptoms are mostly chronic rather than episodic
- only one organ system is repeatedly involved
- fever or infection features dominate
- episodes are consistently meal-linked and food allergy has not been evaluated
- another condition better fits the picture
- repeated episodes lack objective evidence despite appropriate formal evaluation
Many conditions can mimic MCAS, as Weiler (2020) and Ahn and colleagues (2026) describe in their reviews of mimickers. Our guide to MCAS testing explains how a formal evaluation works.
Frequently asked questions
These short answers cover the questions that come up most often.
Can stress trigger an MCAS flare?
Stress is reported as a possible trigger context in some patients. Stress-related symptoms are nonspecific and do not prove MCAS.
Can food trigger an MCAS flare?
Food-associated episodes can occur. Recurrent meal-linked reactions also need evaluation for IgE-mediated food allergy or other food-related diagnoses, and this article does not recommend a blanket low-histamine diet.
Can an MCAS flare happen without hives?
Yes. Hives are not required. Under strict systemic criteria, though, the episode should still show a compatible abrupt, multisystem pattern rather than one isolated symptom.
Can an MCAS flare cause fever?
Fever is not a typical defining feature of an MCAS episode. Infection and other inflammatory causes can mimic or trigger symptoms, so fever should prompt consideration of another cause.
Can surgery trigger an MCAS flare?
Surgery and procedures combine physiologic stress with medication exposures that may provoke mediator release in susceptible patients. The strongest evidence comes from mastocytosis and broader mast-cell-disorder literature, not MCAS-specific trials. People with a diagnosed mast-cell disorder should discuss perioperative planning with their medical and anesthesia teams.
Can symptoms flare during a menstrual period?
Some patients report cyclical symptom changes, but evidence is insufficient to define menstruation as a universal MCAS trigger.
How long do mast-cell flares last?
Strict systemic episodes generally resolve within several hours, while the broader patient-used term “flare” has no validated duration. Fatigue can last longer after a severe event.
When should tryptase be checked?
Timing matters when recurrent severe episodes are being formally evaluated for MCAS. Do not delay emergency care to obtain a sample. Our page on MCAS testing covers the details.
What is the difference between an MCAS flare and a histamine flare?
MCAS concerns systemic mast-cell mediator activation, and histamine is only one mediator. “Histamine flare” is broader language that is not specific to MCAS. For general recovery guidance, see our histamine flare recovery guide.
References
- Lee E, Picard M. Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach. Allergy Asthma Clin Immunol. 2025;21:49. doi:10.1186/s13223-025-00998-9. PMID:41272881.
- Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: Current understanding and research needs. J Allergy Clin Immunol. 2024;154(2):255–263. doi:10.1016/j.jaci.2024.05.025. PMID:38851398.
- Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883–896. doi:10.1016/j.jaci.2019.08.023. PMID:31476322.
- Valent P, Akin C, Bonadonna P, et al. Mast cell activation syndrome: Importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018;142(3):1008–1010. doi:10.1016/j.jaci.2018.06.004. PMID:29928922.
- Weiler CR. Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):498–506. doi:10.1016/j.jaip.2019.08.022. PMID:31470118.
- Valent P, Akin C, Hartmann K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere. 2021;5(11):e646. doi:10.1097/HS9.0000000000000646. PMID:34901755.
- Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124–176. doi:10.1016/j.anai.2023.09.015. PMID:38108678.
- Ahn C, Galván Calle CA, Bernstein JA. Mast Cell Activation Syndrome and Mimickers. Immunol Allergy Clin North Am. 2026;46(2):385–400. doi:10.1016/j.iac.2026.01.014. PMID:41932754.
